Ardelyx, Announced FDA Approval Of XPHOZAH, First-in-Class Phosphate Absorption Inhibitor
Portfolio Pulse from Charles Gross
Ardelyx, Inc. (NASDAQ:ARDX) announced that the U.S. Food and Drug Administration (FDA) has approved XPHOZAH (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis. XPHOZAH is a single tablet taken twice daily that offers a first-in-class mechanism of action that blocks phosphate absorption through its primary pathway.
October 17, 2023 | 11:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ardelyx's FDA approval for XPHOZAH could potentially boost the company's stock as it opens up a new revenue stream.
The FDA approval of XPHOZAH, a first-in-class phosphate absorption inhibitor, is a significant milestone for Ardelyx. This approval opens up a new revenue stream for the company, which could potentially boost its stock. The news is highly relevant as it directly pertains to Ardelyx and its product portfolio.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100